Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)

被引：0
|
作者：
Busch, Martin [1 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 3, Jena, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-07
引用
收藏
页码：S147 / S148
页数：2
相关论文
共 50 条
  • [41] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Sofyan M. Radaideh
    George W. Sledge
    [J]. Breast Cancer Research and Treatment, 2008, 111 : 203 - 208
  • [42] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Radaideh, Sofyan M.
    Sledge, George W.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (02) : 203 - 208
  • [43] Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
    Lafayette, Richard
    Kristensen, Jens
    Stone, Andrew
    Floege, Juergen
    Tesar, Vladimir
    Trimarchi, Hernan
    Zhang, Hong
    Eren, Necmi
    Paliege, Alexander
    Reich, Heather N.
    Rovin, Brad H.
    Barratt, J.
    [J]. LANCET, 2023, 402 (10405): : 859 - 870
  • [44] Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
    Ascierto, P. A.
    Del Vecchio, M.
    Robert, C.
    Mackiewicz, A.
    Chiarion-Sileni, V.
    Arance Fernandez, A. M.
    Schmidt, H.
    Lebbe, C.
    Bastholt, L.
    Hamid, O.
    Rutkowski, P.
    McNeil, C.
    Garbe, C.
    Loquai, C.
    Dreno, B.
    Thomas, L.
    Grob, J. J.
    Hennicken, D.
    Qureshi, A.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [45] A PHASE 3, NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL WITH FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER VS. ESOMEPRAZOLE IN CHINESE PATIENTS WITH EROSIVE ESOPHAGITIS
    Xiao, Yinglian
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S583 - S583
  • [46] Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)
    Jia, Weiping
    Ma, Jianhua
    Miao, Heng
    Wang, Changjiang
    Wang, Xiaoyue
    Li, Quanmin
    Lu, Weiping
    Yang, Jialin
    Zhang, Lihui
    Yang, Jinkui
    Wang, Guixia
    Zhang, Xiuzheng
    Zhang, Min
    Sun, Li
    Yu, Xuefeng
    Du, Jianling
    Shi, Bingyin
    Xiao, Changqing
    Zhu, Dalong
    Liu, Hong
    Zhong, Liyong
    Xu, Chun
    Xu, Qi
    Liang, Ganxiong
    Zhang, Ying
    Li, Guangwei
    Gu, Mingyu
    Liu, Jun
    Ning, Zhiqiang
    Ji, Linong
    [J]. DIABETES, 2019, 68
  • [47] Baseline characteristics in patients maintaining q12 and q16 dosing vs. those with shortened dosing intervals-Phase3 PULSAR trial
    Arnold, Jennifer
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (09): : 1027 - 1027
  • [48] TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO
    Ettrich, T. J.
    Berger, A. W.
    Decker, T.
    Hofheinz, R. D.
    Heinemann, V.
    Hoffmann, T.
    Hebart, H. F.
    Herrmann, T.
    Hannig, C-V.
    Buechner-Steudel, P.
    Bartholomaeus, H.
    Guethle, M.
    Perkhofer, L.
    Seufferlein, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [49] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
  • [50] Week 48 results of a phase 3 randomised controlled trial of B/F/TAF vs. DTG plus F/TDF as initial treatment in adults with HIV/HBV coinfection (ALLIANCE)
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Koening, Ellen
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Zhang, Fujie
    Rahman, Sophia
    Brogan, Michelle D'Antoni
    Wang, Hongyuan
    Hindman, Jason
    Martin, Hal
    Mack, Frank
    Baeten, Jared
    [J]. HIV MEDICINE, 2023, 24 : 54 - 54
12345